LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article: Systemic sclerosis with morphea-like plaques histopathologically mimicking cutaneous B-cell lymphoma.

    Aragon Sierra, Ana M / Hwang, Angelina S / Kechter, Jacob / Mangold, Aaron R / Nagaraja, Vivek / DiCaudo, David J

    JAAD case reports

    2024  Volume 47, Page(s) 32–34

    Language English
    Publishing date 2024-03-08
    Publishing country United States
    Document type Case Reports
    ZDB-ID 2834220-3
    ISSN 2352-5126
    ISSN 2352-5126
    DOI 10.1016/j.jdcr.2024.02.028
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Topical Ruxolitinib in the Treatment of Necrobiosis Lipoidica: A Prospective, Open-Label Study.

    Hwang, Angelina S / Kechter, Jacob A / Li, Xing / Hughes, Alysia / Severson, Kevin J / Boudreaux, Blake / Bhullar, Puneet / Nassir, Shams / Yousif, Miranda / Zhang, Nan / Butterfield, Richard J / Nelson, Steven / Xing, Xianying / Tsoi, Lam C / Zunich, Samantha / Sekulic, Aleksandar / Pittelkow, Mark / Gudjonsson, Johann E / Mangold, Aaron

    The Journal of investigative dermatology

    2024  

    Abstract: Necrobiosis lipoidica (NL) is a rare granulomatous disease. There are few effective treatments for NL. We sought to investigate the efficacy and safety of the Jak1/2 inhibitor, ruxolitnib, in the treatment of NL and identify the biomarkers associated ... ...

    Abstract Necrobiosis lipoidica (NL) is a rare granulomatous disease. There are few effective treatments for NL. We sought to investigate the efficacy and safety of the Jak1/2 inhibitor, ruxolitnib, in the treatment of NL and identify the biomarkers associated with the disease and treatment response. We conducted an open-label, phase 2 study of ruxolitinib in 12 patients with NL. We performed transcriptomic analysis of tissue samples before and after treatment. At week 12, the mean NL lesion score decreased by 58.2% (SD = 28.7%, P = .003). Transcriptomic analysis demonstrated enrichment of type I and type II IFN pathways in baseline disease. Weighted gene coexpression network analysis demonstrated post-treatment changes in IFN pathways with key hub genes IFNG and signal transducer and activator of transcription 1 gene STAT1. Limitations include small sample size and a study group limited to patients with <10% body surface area. In conclusion, ruxolitinib is an effective treatment for NL and targets the key pathogenic mediators of the disease.
    Language English
    Publishing date 2024-02-27
    Publishing country United States
    Document type Journal Article
    ZDB-ID 80136-7
    ISSN 1523-1747 ; 0022-202X
    ISSN (online) 1523-1747
    ISSN 0022-202X
    DOI 10.1016/j.jid.2023.11.027
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui VI Zs.124: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Primary cutaneous diffuse large B-cell lymphoma, leg type, presenting as subcutaneous nodules: Case series and comparison of treatment outcomes.

    Besch, Jake G / Kechter, Jacob / Hwang, Angelina / Shahin, Ahmad / Bhullar, Puneet / Puri, Pranav / Butterfield, Richard / Costello, Collin / Rule, William / Rosenthal, Allison / DiCaudo, David J / Pittelkow, Mark / Mangold, Aaron

    JAAD case reports

    2023  Volume 41, Page(s) 81–84

    Language English
    Publishing date 2023-09-26
    Publishing country United States
    Document type Case Reports
    ZDB-ID 2834220-3
    ISSN 2352-5126
    ISSN 2352-5126
    DOI 10.1016/j.jdcr.2023.08.042
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: Oral Baricitinib in the Treatment of Cutaneous Lichen Planus.

    Hwang, Angelina / Kechter, Jacob / Do, Tran / Hughes, Alysia / Zhang, Nan / Li, Xing / Wasikowski, Rachael / Brumfiel, Caitlin / Patel, Meera / Boudreaux, Blake / Bhullar, Puneet / Nassir, Shams / Yousif, Miranda / DiCaudo, David J / Fox, Jennifer / Gharaee-Kermani, Mehrnaz / Xing, Xianying / Zunich, Samantha / Branch, Emily /
    Kahlenberg, J Michelle / Billi, Allison C / Plazyo, Olesya / Tsoi, Lam C / Pittelkow, Mark R / Gudjonsson, Johann E / Mangold, Aaron R

    medRxiv : the preprint server for health sciences

    2024  

    Abstract: Background: Cutaneous lichen planus (LP) is a recalcitrant, difficult-to-treat, inflammatory skin disease characterized by pruritic, flat-topped, violaceous papules on the skin. Baricitinib is an oral Janus kinase (JAK) 1/2 inhibitor that interrupts the ...

    Abstract Background: Cutaneous lichen planus (LP) is a recalcitrant, difficult-to-treat, inflammatory skin disease characterized by pruritic, flat-topped, violaceous papules on the skin. Baricitinib is an oral Janus kinase (JAK) 1/2 inhibitor that interrupts the signaling pathway of interferon (IFN)-γ, a cytokine implicated in the pathogenesis of LP.
    Methods: In this phase II trial, twelve patients with cutaneous LP received baricitinib 2 mg daily for 16 weeks, accompanied by in-depth spatial, single-cell, and bulk transcriptomic profiling of pre-and post-treatment samples.
    Results: An early and sustained clinical response was seen with 83.3% of patients responsive at week 16. Our molecular data identified a unique, oligoclonal IFN-γ, CD8+, CXCL13+ cytotoxic T-cell population in LP skin and demonstrate a rapid decrease in interferon signature within 2 weeks of treatment, most prominent in the basal layer of the epidermis.
    Conclusion: This study demonstrates the efficacy and molecular mechanisms of JAK inhibition in LP.
    Language English
    Publishing date 2024-01-11
    Publishing country United States
    Document type Preprint
    DOI 10.1101/2024.01.09.24300946
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top